EMA Lapsed: Thorinane (enoxaparin sodium) — Pharmathen S.A.

View source ↗

Summary

EMA has lapsed the marketing authorisation for Thorinane (enoxaparin sodium) by Pharmathen S.A., with the therapeutic area being venous thromboembolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Thorinane (enoxaparin sodium)

Snippet

Status: Lapsed. Therapeutic area: Venous Thromboembolism. MAH: Pharmathen S.A.. Decision date: 05/09/2017